Table 5 Safety of IPTsc during intervention period

Dicko [23]

Kambila

SP (bimonthly)

No severe adverse event

No data available

Control

Clarke [24]

Bondo

SP + AQ (four-monthly)

19 (0.79 %) severe adverse events (problems of balance, dizziness, feeling faint, nausea or vomiting)

6 (0.23 %) adverse events graded as moderate

49 (1.9 %) mild events (nausea, headache, prurititis)

Mild events were more frequent among children receiving active drugs than among controls

Placebo

4 (0.17 %) severe adverse events (problems of balance, dizziness, feeling faint, nausea or vomiting and one severe skin reaction)

7 (0.30 %) moderate adverse events

33 (1.4 %) mild events (nausea, headache, prurititis)

Barger [25]

Kollé

SP + AS

Most adverse events: headache, abdominal pain and respiratory symptoms.

–

AQ + AS

Placebo

Nankabirwa [26]

Tororo

SP

No severe adverse events.

Only mild (92 %) and moderate (8 %), with no difference between treatment groups

–

SP + AQ

DP

Placebo

Nankabirwa [27]

Tororo

DP (monthly)

6 (2.5 %) severe adverse events

Mild events were more frequent in the placebo group than the intervention arms

DP (three to five monthly)

1 (0.40 %) death (due to acute lymphoblastic leukaemia); 5 (2 %) severe adverse events

Placebo

3 (1.2 %) severe adverse events